Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedU.S. GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue was recognized under the agreement with the Mayo Foundation, research and development and patent expenses decreased due to lower testing costs related to MN-166 and clinical trial costs for MN-001, and general and administrative expenses increased due to higher professional fees and stock-based compensation expense.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | U.S. GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | 186,984 U.S. dollars (yen equivalent: ¥29,990 thousand) |
| Operating profit | -2,835,806 U.S. dollars (yen equivalent: △¥454,834 thousand) |
| Ordinary income | -2,586,258 U.S. dollars (yen equivalent: △¥414,809 thousand) |
| Profit attributable to owners of the parent | -2,586,258 U.S. dollars (yen equivalent: △¥414,809 thousand) |
| Net income per share | △US$0.05 (△¥8) |
| Equity ratio | End of the current fiscal period 92.3% / End of previous period 91.2% |
| Total assets | 42,704,854 U.S. dollars (yen equivalent: ¥6,849,431 thousand) |
| Net assets | 39,407,234 U.S. dollars (yen equivalent: ¥6,320,526 thousand) |
| Cash flows from operating activities | -3,470,213 U.S. dollars (yen equivalent: △¥556,587 thousand) |
| Cash flows from investing activities | -10,825 U.S. dollars (yen equivalent: △¥1,736 thousand) |
| Cash and cash equivalents at end of period | 27,329,415 U.S. dollars (yen equivalent: ¥4,383,364 thousand) |
| Annual Dividend Forecast | 0 U.S. dollars (per share) → 0 U.S. dollars (per share) |
| Segment revenue | Single business segment (no segment-specific figures disclosed) |
| Segment profit | Single business segment (no segment-specific figures disclosed) |
| Depreciation and amortization | 4,260 U.S. dollars (yen equivalent: ¥683 thousand) |
| Disclosure regarding the going concern assumption | No applicable matters |
| Issued Shares at Period-End | 49,221,246 shares |
| Factors Behind Changes in Business Performance | Revenue was recognized under the agreement with the Mayo Foundation, research and development and patent expenses decreased due to lower testing costs related to MN-166 and clinical trial costs for MN-001, and general and administrative expenses increased due to higher professional fees and stock-based compensation expense. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development and patent expenses decreased because the Company recognized revenue under its agreement with the Mayo Foundation, while testing costs related to MN-166 decreased by US$0.4 million and clinical trial costs for MN-001 decreased by US$0.1 million. General and administrative expenses increased due to higher professional fees and stock-based compensation expense.